Clinical Trial Update: A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating safety, tolerability, and pharmacokinetics of GDC-0032 (taselisib) in combination with docetaxel or paclitaxel in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• GDC-0032 (taselisib) (taselisib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer, Non-small Lung Cancer | Phase 1 | Status: COMPLETED